Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
09 Dezembro 2024 - 6:05PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, announced it will present new data at the
2024 San Antonio Breast Cancer Symposium® (SABCS), including a
spotlight presentation on a breast cancer risk assessment tool that
combines a polygenic score for all ancestries.
Additional new data will show how Myriad’s
second-generation tumor-informed molecular residual disease (MRD)
assay demonstrated high sensitivity, specificity and measurement
accuracy, which, together, will facilitate improved resolution in
residual-disease detection and extend lead times in recurrence
detection.
“We are very excited to share validation data of
our MRD assay. SABCS gives us the opportunity to showcase our
clinical expertise in the prevention and treatment of early and
advanced breast cancer,” said George Daneker, MD, President and
Chief Clinical Officer, Oncology, Myriad Genetics. “Myriad is one
of the only labs that can offer germline and tumor genomic testing,
combined with customizable workflow solutions and point-of-care
patient education sessions. Our test results are supported by
treatment-focused reporting, concordance checks between germline
and tumor genomic results, and a summary sheet designed to help
oncologists and breast surgeons interpret actionable insights more
effectively.”
Myriad Genetics Data
Presentations
Spotlight Presentation: Session
16, PS16-01: Polygenic Risk Date: Thursday, Dec.
12, 2024, 5:30-7:00 pm (CST), Hemisfair Ballroom 3
Presenter: Timothy Simmons, PhD, Biostatistician
III, Myriad Genetics The presentation will share longitudinal
validation in the UK Biobank of a breast cancer risk assessment
tool that combines a polygenic score for all ancestries with
traditional risk factors.
Rapid-Fire Presentation: RF1-06
Date: Wednesday, Dec. 11, 2024, 12:00-12:50 pm
(CST), Hall 1 Presenter: Katie Johansen Taber,
PhD, Vice President, Clinical Product Research & Partnerships,
Myriad Genetics Dr. Johansen Taber will share data detailing the
association of polygenic-based breast cancer risk prediction with
patient management.
Poster Presentation: P2-04-23
Date: Wednesday, Dec. 11, 2024, 5:30-7:00 pm
(CST), Halls 2-3 Presenter: Ashley Acevedo, PhD,
Staff Computational Scientist, Myriad Genetics This poster shares
the analytical validation of a high-definition tumor-informed
Molecular Residual Disease (MRD) assay to demonstrate robust
detection at low-tumor fractions, which are common in breast
cancer.
Poster Presentation: P3-02-10
Date: Thursday, Dec. 12, 2024, 12:30-2:00 pm
(CST), Halls 2-3 Presenter: Holly Pederson, MD,
Cleveland Clinic Dr. Pederson will share her evaluation of a
polygenic risk score as a predictor of breast cancer,
triple-negative breast cancer, and early-onset disease in Hispanic
women.
In addition to data presentations, Myriad will
welcome attendees to its booth (#1327) during exhibition hours.
Among the Myriad products highlighted in the company’s SABCS
exhibit are:
- MyRisk® Hereditary Cancer Test evaluates 48 genes to help
healthcare providers identify their patients’ risk of developing 11
different types of hereditary cancer. MyRisk’s clear, actionable
results are the foundation for personalized care plans to help
patients make confident, informed decisions about medical
management. MyRisk with RiskScore® provides unaffected patients
with a comprehensive, personalized assessment of the five-year risk
and remaining lifetime risk of developing breast cancer.
- Precise Tumor® Molecular Profile Test is a pan-cancer solid
tumor comprehensive genomic profiling test that helps clinicians
with straightforward interpretations, prioritization of therapies,
and the next steps specific to each patient’s genomic result.
- MyChoice® CDx is one of the most comprehensive homologous
recombination deficiency (HRD) tests available, enabling physicians
to identify patients with tumors that have lost the ability to
repair double-stranded DNA breaks, resulting in increased
susceptibility to DNA-damaging drugs such as platinum drugs or PARP
inhibitors. The MyChoice test comprises tumor sequencing of the
BRCA1 and BRCA2 genes and a composite of three proprietary
technologies (loss of heterozygosity, telomeric allelic imbalance
and large-scale state transitions).
- EndoPredict® Breast Cancer Prognostic Test is for patients with
ER+, HER2-, node negative or node positive breast cancer. The test
provides three individualized results used to help determine the
most appropriate breast cancer treatment.
About Myriad Genetics Myriad
Genetics is a leading genetic testing and precision medicine
company dedicated to advancing health and well-being for all.
Myriad develops and offers genetic tests that help assess the risk
of developing disease or disease progression and guide treatment
decisions across medical specialties where genetic insights can
significantly improve patient care and lower healthcare costs. For
more information, visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
that the company will present new data at SABCS and that the
company’s new data that will be shared at SABCS will show how the
company’s second-generation tumor-informed MRD assay demonstrated
high sensitivity, specificity and measurement accuracy, which,
together, will facilitate improved resolution in residual-disease
detection and extend lead times in recurrence detection. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on February 28, 2024, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor Contact Matt Scalo (801)
584-3532 IR@myriad.com
Media Contact Glenn Farrell (385)
318-3718 PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024